How Adaptive Oncology Trials Are Accelerating The Path To Approval

Phase 2 and 3 oncology trials run nearly 50% longer than studies in other therapeutic areas. With every day of delay costing sponsors an estimated $800,000 in lost sales and $40,000 in trial expenses, the pressure to streamline cancer drug development has never been greater. Adaptive trial designs offer a path forward, allowing sponsors to modify studies in real time based on accumulating data, enrich datasets at specific dose levels, and respond to regulatory expectations under Project Optimus.

This whitepaper draws on insights from Vanessa Beddo, Ph.D., Vice President, Biostatistical Consulting at Allucent, to examine how sponsors are applying adaptive methodologies across phase 1 through phase 3 oncology programs.

What you will learn:

How Bayesian dose-finding designs, including the FDA fit-for-purpose BOIN design, are replacing the 3+3 model in phase 1 oncology trials
Why seamless phase 2/3 transitions can rescue programs caught short by Project Optimus dose optimization expectations
How biomarker-enabled adaptations sharpen patient selection and support regulatory and ethical alignment before late-phase studies
What the FDA’s 2023 neuroblastoma approval signals about real-world external controls as accelerated registrational pathways
How interactive monitoring tools allow sponsors to weave safety, efficacy, and translational data into real-time trial decisions

First name

Last name

Business Email Address

Company name

Company Type

Job title

Job Function

Country

I acknowledge and agree to the use of my contact information to receive messages about offerings by Questex, its brands, affiliates and/or third-party partners, consistent with Questex Privacy Policy.